To test whether ghrelin variants could play a role in modulating some aspects of the obese phenotype during childhood. DESIGN: We screened the ghrelin gene in 300 Italian obese children and adolescents (mean age 10.573.2 y; range 4-19 y) and 200 controls by using the single-strand conformation polymorphism and the restriction fragment length polymoprhism analysis. RESULTS: No mutations were detected with the exception of two previously described polymorphisms, Arg51Gln and Leu72Met. For both variations, allelic frequencies were similar between patients and controls. Interestingly, we showed that the Leu72Met polymorphism was associated with differences in the age at obesity onset. Patients with the Met72 allele became obese earlier than homozygous patients for the wild Leu72 allele. The logrank test comparing the plots of the complement of Kaplan-Meier estimates between the two groups of patients was statistically significant (Po0.0001). CONCLUSIONS: It is unlikely that ghrelin variations cause the obesity due to single-gene mutations. The Leu72Met polymorphism of the ghrelin gene seems to play a role in anticipating the onset of obesity among children suggesting, therefore, that ghrelin may be involved in the pathophysiology of human adiposity.
Introduction
Ghrelin is a recently discovered ligand for the growth hormone secretagogue receptor (GHS-R), originally isolated from the rat stomach, 1 but also produced by the intestine, placenta and pituitary gland. Although ghrelin is a potent GH secretagogue in vitro and in vivo, 2 the activity of this peptide is not restricted to the hypothalamic-pituitary axis. 3 In fact, because of the distribution of GHS receptors on agouti-related protein (AGRP) and neuropeptide-Y ( NPY) neurons (two populations of orexigenic neurons) in the arcuate nuclei of the hypothalamus, it has been hypothesized that ghrelin could be involved in energy homeostasis. 4 Many studies support this hypothesis. Exogenous ghrelin induces adiposity in rodents by stimulating a sharp increase in food intake, as well as lowered fat utilization. 5 The orexigenic effect of ghrelin has also been documented in humans, reporting hunger as the only sensation after ghrelin injection. [6] [7] In spite of its orexigenic function, obese subjects seem to have lower plasma ghrelin levels than agematched lean subjects. 8 Ghrelin appears to have the opposite effects of leptin, and these two hormones might really be complementary players of one regulatory system that has developed to inform the central nervous system about the current status of acute and chronic energy balance. Obesity arises from changes to the delicate mechanism regulating energy expenditure and food intake. 10 Childhood obesity is rapidly becoming a global epidemic condition. Its immediate adverse effects include orthopedic complications, sleep apnea and psychosocial disorders. Furthermore, childhood obesity increases the risk of obesity in adulthood.
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Analyses made on twins and adopted children as well as a great deal of researches over the last decade have shown that obesity has a considerable genetic component. 12, 13 We report the molecular screening of the ghrelin gene in Italian obese children and adolescents. The aim of this study is to test whether ghrelin genetic variations could play a role in predisposing to early-onset obesity, or in modulating some aspects of the obese phenotype during childhood.
Materials and methods
The study was carried out on 300 patients (mean age 10. 573.2 y; range 4-19 y) referred, from October 1997 to April 2002, to the Department of Pediatrics at the Second University of Naples for a weight reduction program, and on 200 lean controls (mean age 10.472.8 y; range 3-16 y) belonging to the same geographic area.
Obesity was defined when body mass index (BMI calculated as weight in kilograms divided by the square of height in meters) exceeded the 971 percentile for sex and age according to reference values. 14 The mean of the s.d. scores (Z-score) relative to BMI percentiles was 3.4371.9 (range 2.1-8.3). The average age at obesity onset was 4.772.5 y (range 1-11 y). To assess the age of obesity onset during early childhood, the records of the patients were reviewed. In these records, the anthropometric measurements made in the pediatrician's surgeries within the ambit of children's health balances made annually are reported. Body weights were evaluated by balance beam scale and wall-mounted stadiometers were used to measure the height. All the measurements were repeated twice. After informed consent, a blood sample was drawn from each patient at the end of an overnight fast. The serum was frozen at À101C until analysed. A double-antibody radio immunoassay (Human Leptin RIA Kit, Linco Research, St Charles, MO, USA) for serum leptin measurement was used. The sensitivity cutoff for the leptin assay is 0.5 ng/ml; the intra-and interassay variation coefficients were 10.8 and 7%, respectively. Immunoreactive insulin was assayed by IMX (Abbott Diagnostics, Santa Clara, CA, USA). The mean intraand interassay coefficients of variations were 4.7 and 7.2%, respectively.
Genomic DNA was collected from nucleated white blood cells. The human ghrelin gene is encoded by four exons as a preprohormone. 15 The mature ghrelin product has 28 amino acids and is encoded by parts of the first two exons. 15 Two couples of primers, covering exon 1 and 2 were designed from a genomic sequence (acc. no. AF296558; NCBI) in order to encompass the entire mature ghrelin product. They generate a 262 bp fragment (GREL1F ¼ 5 0 CAG AGG CAC ATG AGA AGG GGA 3 0 , GREL1R ¼ 5 0 -CTT CCA GAA ACA GTG AGG TCA-3 0 ) and a 278 bp fragment (GREL2F ¼ 5 0 -TGA CCT CAC TGT TTC TGG AAG-3 0 , GREL2R ¼ 5 0 -GGA CCC TGT TCA CTG CCA C-3 0 ), respectively. Every cycle of the polymerase chain reaction (PCR) except the first one (961C for 4.30 min) was performed as follow: 961C for 30 s, 641C for 30 s and 721C for 30 s. The PCR products were screened using the single-strand conformation polymorphism (SSCP) analysis as previously described. 16 Two previously described polymorphisms, Arg51Gln (G152A) and Leu72Met (C214A), which could not be distinguished by SSCP, were directly detected by digesting the 278 bp fragment with AvaI (Arg51 allele: fragments of 168 and 110 bp) and BrsI (Leu72 allele: fragments of 172 and 106 bp). Restriction patterns were visualized on 2% agarose gels stained with ethidium bromide.
Values are given as the mean7s.d. Associations between the gene variant and phenotypes were analyzed by using the analysis of variance (ANOVA). The w 2 test allowed us to estimate allelic frequencies. A logistic regression was used to predict the odds for subjects (patients and controls) carrying the 72Met polymorphism to become obese. To evaluate the risk of obese children carrying the rare allele to develop obesity earlier than obese children homozygous for the common variant, we divided the sample into two groups using as cutoff the median of age at onset and a logistic regression equation was generated to predict the natural log of the odds. To evaluate the age-dependent hazard rate of developing obesity for each patient category (ie, heterozygotes plus homozygotes for the Met72 allele vs homozygotes for the ghrelin wild allele), the Kaplan-Meier estimates were calculated. The plots of the complement of Kaplan-Meier estimates for each group of patients were compared by a logrank test. Significance was defined as Po0.05.
Results
SSCP screening failed to detect any mutation. Two obese subjects (0.6%) and four lean controls (2%) were found to be heterozygotes for theArg51Gln variant. This result indicates that this variant is not implicated in predisposing to earlyonset obesity. In all, 32 patients (10.3%) were heterozygotes and four (1.3%) homozygotes for the Leu72Met polymorphism. This mutation was also present in the heterozygous or homozygous state in 26 (13%) and four (2%) controls, respectively. Allelic frequencies were (0.066) and (0.085) in patients and controls, respectively (w 2 : 0.5, P40.1). Children carrying the 72Met polymorphism did not show a higher risk to become obese with respect to children homozygous for the common allele (odds ratio 0.8, P ¼ 0.4, 95 % CI 0.5-1.3). This suggests that even this variation is not primarily related to obesity. When comparing the age, BMI z-scores, leptin and insulin levels of the obese patients with the Leu72Met polymorphism (heterozygotes plus homozygotes), with the homozygotes for the wild allele, we found no difference (Table 1) . Interestingly, we showed that this polymorphism was associated with a statistically significant difference in the age of obesity onset. The difference remained statistically significant after adjustment for sex (Table 1) . Using as cutoff the median of age at onset, patients with the Leu72Met variation showed a 6.7 fold higher risk to become obese earlier (Odds Ratio: 6.7, Po0.001, 95% CI 2.0-22.6). Figure 1 shows the different plots of the complement of KaplanMeier estimates between the two groups of patients. The difference between the two plots estimated by the logrank ghrelin Leu72Met polymorphism is associated with a precocious onset of obesity EM del Giudice et al test was statistically significant (Po0.0001) and represented by every follow-up time the cumulative rate difference among the two groups. Therefore, in children predisposed to become obese, the Met72 allele appears as a genetic cause able to anticipate the onset of obesity.
Discussion
The Leu72Met substitution is a nonconservative amino-acid change in the protein sequence of the prepro-ghrelin Cterminal tail. This common polymorphism has been found in a group of obese Swedish adults 17 as well as in a group of obese French children and adolescents. 18 In both cases, the Met72 allele was associated with a trend towards a lower age of the self-reported onset of obesity. These findings were not confirmed in a group of extremely obese German children. 19 Reviewing the records of 300 Italian obese children revealed that the patients with the prepro-ghrelin Met72 allele became obese earlier than the homozygous patients for the wild Leu72 allele. The Leu72Met mutation lies outside the region where the mature ghrelin product is encoded 1 and, therefore, its functional significance remains uncertain. Given that ghrelin is an orexigenic peptide, this mutation would either have to cause an increased expression or a gain in function of the peptide. It could be in linkage disequilibrium with a nearby mutation at a locus that has a functional relvance (eg, the promoter region). But, considering that the leucine at position 72 is highly conserved among the different mammalian species 20 and that the role of the prepro-ghrelin C-terminal peptide is still undetermined, the Leu72Met substitution might per se have a functional significance. It might alter protein processing modifying, in this way, ghrelin secretion and/or activity. We conclude that, although a few mutations might be missed by SSCP, it is unlikely that ghrelin variations could be a common cause of the rare form of obesity due to singlegene mutations. However the possibility exists that in an essentially polygenic trait such as common childhood obesity, the Leu72Met polymorphism could play a role in anticipating the onset of disease. Therefore, considering that early childhood obesity is the dominant predictor of obesity 5 years later 21 and that, to be effective, strategies to prevent childhood obesity must begin at a very early age, we consider of particular interest the study of this widely distributed polymorphism. ghrelin Leu72Met polymorphism is associated with a precocious onset of obesity EM del Giudice et al
